Intravenous AICAR during hyperinsulinemia induces systemic hemodynamic changes but has no local metabolic effect.

Keyphrases

• Metabolic Effects 100%
• Hyperinsulinemia 100%
• 5-aminoimidazole-4-carboxamide Riboside 100%
• Systemic Hemodynamics 100%
• Placebo 36%
• Insulin 36%
• Blood Pressure 27%
• Heart Rate 27%
• Erythrocytes 18%
• Glucose Uptake 18%
• Glucose Infusion Rate 18%
• Healthy Individuals 9%
• Plasma Concentration 9%
• Plethysmography 9%
• Skeletal muscle 9%
• Forearm 9%
• Whole-body 9%
• Hyperinsulinemic-euglycemic Clamp 9%
• Vasodilation 9%
• Skeletal muscle Glucose Uptake 9%
• Forearm Blood Flow 9%
• AMPK Activator 9%
• Paired Data 9%
• AMPK Activation 9%

Medicine and Dentistry

• Hemodynamic 100%
• Hyperinsulinemia 100%
• 5 Amino 4 Imidazolecarboxamide Riboside 100%
• Placebo 36%
• Glucose Uptake 27%
• Blood Pressure 27%
• Infusion 18%
• Glucose Infusion 18%
• Infusion Rate 18%
• AMP-Activated Protein Kinase 18%
• Erythrocyte 18%
• Skeletal Muscle 18%
• Plethysmography 9%
• 5 Amino 4 Imidazolecarboxamide 9%
• Vasodilatation 9%
• Forearm Blood Flow 9%
• Table Salt 9%

INIS

• ribosides 100%
• glucose 45%
• insulin 36%
• infusion 36%
• humans 27%
• uptake 27%
• blood pressure 27%
• muscles 18%
• concentration 18%
• plasma 18%
• erythrocytes 18%
• data 9%
• comparative evaluations 9%
• administration 9%
• in vivo 9%
• blood flow 9%
• vasodilation 9%